Emerald Advisers LLC Acquires Shares of 2,332,680 Savara Inc (NASDAQ:SVRA)

Emerald Advisers LLC bought a new position in Savara Inc (NASDAQ:SVRA) during the fourth quarter, according to its most recent 13F filing with the SEC. The fund bought 2,332,680 shares of the company’s stock, valued at approximately $7,161,000. Emerald Advisers LLC owned about 1.36% of Savara as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in SVRA. Cibc World Markets Corp bought a new stake in Savara during the fourth quarter worth approximately $33,000. KLP Kapitalforvaltning AS bought a new position in shares of Savara during the 4th quarter valued at approximately $41,000. Virtu Financial LLC purchased a new stake in Savara during the 3rd quarter valued at $67,000. BNP Paribas Financial Markets lifted its position in Savara by 258.9% in the third quarter. BNP Paribas Financial Markets now owns 25,693 shares of the company’s stock worth $109,000 after buying an additional 18,534 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its stake in Savara by 14.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 36,390 shares of the company’s stock worth $112,000 after buying an additional 4,732 shares during the period. 87.93% of the stock is currently owned by hedge funds and other institutional investors.

Savara Trading Down 1.4 %

Shares of SVRA opened at $2.82 on Friday. The firm has a market capitalization of $483.97 million, a price-to-earnings ratio of -6.56 and a beta of 0.60. The company has a debt-to-equity ratio of 0.13, a current ratio of 17.70 and a quick ratio of 17.70. Savara Inc has a 1-year low of $2.26 and a 1-year high of $5.34. The company has a 50-day moving average of $2.73 and a 200 day moving average of $3.31.

Analysts Set New Price Targets

SVRA has been the topic of several recent analyst reports. Wells Fargo & Company began coverage on shares of Savara in a research note on Friday, December 20th. They issued an “overweight” rating and a $8.00 target price on the stock. JMP Securities reissued a “market outperform” rating and issued a $9.00 price objective on shares of Savara in a research report on Thursday, December 19th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, Savara currently has a consensus rating of “Moderate Buy” and a consensus price target of $8.83.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.